Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  04/07/2008
 
Trade Name:  Orencia
 
Generic Name or Proper Name (*):  abatacept
 
Indications Studied:  Moderate to severe polyarticular juvenile idiopathic arthritis
 
Label Changes Summary:  Indicated for reducing signs and symptoms in pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) ages 6 years and older. The safety and effectiveness in pediatric patients < 6 years of age and in pediatric patients for uses other than JIA have not been established Abatacept was studied in 190 patients 6 - 17 years with polyarticular JIA. AEs were generally similar to those seen in adults. Overall frequency of adverse events in the 4-month, lead-in, open-label period of the study was 70%; infections occurred at a frequency of 36%. A total of 6 serious adverse events were reported during the initial 4 months of treatment with abatacept. Information on dosing, PK, immunogenicity, immunization needs, AEs, and clinical study New indication
 
PREA(P):  P
 
Sponsor:  Bristol-Myers Squibb
 
NNPS:  FALSE'
 
Therapeutic Category:  Anti-inflammatory
 
-
-